NIOX products are available in over 50 countries with local teams and distributor networks providing customer support. The company derives a majority of its revenue from Asia Pacific with presence in the EU, US, UK, and other regions. The company launched the new NIOX PRO in December.
Cyborg Score Rationale
NIOX holds a market-leading position in the specialized FeNO diagnostic space with global distribution in 50+ countries and recent product innovation. However, the company faces typical medtech challenges including regulatory dependencies and competitive pressures in respiratory diagnostics.
Top Insights
Dominant position in FeNO measurement with NIOX VERO and newly launched NIOX PRO representing innovation pipeline
Recent product launch and January 2025 trading update suggest positive momentum and renewed investor interest
Failed Keensight acquisition attempt (March 2025) at 81p indicates external validation of value, though execution challenges remain
Asia Pacific revenue concentration presents geographic diversification opportunity and emerging market growth potential
Named Competitors
Spirometry Systems — Traditional lung function testing alternatives